Evans, SJ (2011) Blanket disapproval of all unlicensed indications is wrong. BMJ, 343. d7726. ISSN 0959-8138 DOI: https://doi.org/10.1136/bmj.d7726

Downloaded from: http://researchonline.lshtm.ac.uk/19676/

DOI: 10.1136/bmj.d7726
**Letters** Bevacizumab off-label

**Blanket disapproval of all unlicensed indications is wrong**

BMJ 2011; 343 doi: http://dx.doi.org/10.1136/bmj.d7726 (Published 29 November 2011) Cite this as: BMJ 2011;343:d7726

**Stephen J Evans, professor of pharmacoepidemiology**

1 London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK

stephen.evans@lshtm.ac.uk

“Off-label” covers a variety of situations. Applications for marketing authorisations—licences that lead to a “label”—are made by companies for almost entirely commercial reasons. The company that makes bevacizumab does not apply for an authorisation for use in macular degeneration because it also makes the more expensive licensed product.

This is a failing of the licensing system, in that it relies on companies to do things in the best interests of patients because these usually coincide with their commercial interests. In this situation, they do not.

The General Medical Council and Kyle mistakenly disapprove of all unlicensed indications.1 If it were open (practically and legally) to the NHS to apply for a marketing authorisation, bevacizumab would probably become licensed for this indication, but with pressure from companies and their allies to prevent this, the opportunity to benefit more patients will be lost.

**Notes**

Cite this as: BMJ 2011;343:d7726

**Footnotes**

- Competing interests: None declared.

- SJE is a member of the pharmacovigilance working party at the European Medicines Agency but this is strictly a personal view.

**References**